Elan Expects Tysabri To Capture 50% Of Expanded Multiple Sclerosis Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan says its goal is to grow the MS market, not to destroy Tysabri partner Biogen Idec's Avonex franchise. Patient uptake for Tysabri is "far beyond what we thought it would be," Elan says. The firm is also encouraged by physicians' acceptance of one-year trial data and a desire to establish infusion centers.